Recent Updates
Recently added Catalysts
AGMB Positive Sentiment

Agomab Announces Positive Phase 1 Interim Results with AGMB-447 in Healthy Participants and Initiation of Idiopathic Pulmonary Fibrosis Cohort

Thursday, January 8, 2026 BiopharmaWatch Research 1 min read
Add on Google
Key Takeaway: Agomab Therapeutics has reported positive interim results from its Phase 1 study of AGMB-447, an inhaled small molecule inhibitor targeting ALK5 for the treatment of Idiopathic Pulmonary Fibrosis. The study involved healthy participants and marks a significant step in Agomab's clinical development. The company is now initiating a cohort specifically for Idiopathic Pulmonary Fibrosis.

Market Sentiment Analysis

POSITIVE FACTORS

  • Positive interim results from Phase 1 study.
  • AGMB-447 targets a significant health issue, Idiopathic Pulmonary Fibrosis.
  • The drug is designed as a lung-restricted therapy.

Full Press Release Details

Antwerp, Belgium, January 8, 2026 Agomab Therapeutics NV (‘Agomab’), a clinical-stage biopharmaceutical company focused on fibrosis, today announced positive interim results of the Phase 1 study of AGMB-447 in healthy participants. AGMB-447 is an inhaled lung-restricted small molecule inhibitor of ALK5 (or TGFβR1) intended for the treatment of Idiopathic Pulmonary Fibrosis (IPF).

Frequently Asked Questions

What are the results of the AGMB-447 Phase 1 study?

The Phase 1 study of AGMB-447 reported positive interim results in healthy participants.

What condition is AGMB-447 targeting?

AGMB-447 is intended for the treatment of Idiopathic Pulmonary Fibrosis.

What type of drug is AGMB-447?

AGMB-447 is an inhaled lung-restricted small molecule inhibitor of ALK5.

Who conducted the Phase 1 study?

The Phase 1 study was conducted by Agomab Therapeutics NV.

ShareAdd on Google
Tags: AGMB Viatris Investor Conferences Healthcare Agomab AGMB-447 Idiopathic Pulmonary Fibrosis ALK5 clinical trial
Last updated: Jan 8, 2026

Biotech snapshot

Lead asset
AGMB-129Phase 2
Fibrostenotic Crohn's Disease →